Spatial Epidemiology of Clinical Forms of Cutaneous Leishmania-sis and Treatment Practice: Evidence from Leishmaniasis Re-search and Treatment Center, Northwest Ethiopia
Abstract
Background: We aimed to conduct a comprehensive analysis of cutaneous leishmaniasis’s (CL) clinical polymorphism by examining the relationship between clinical forms, duration of illness, and their spatiotemporal distribution.
Methods: A retrospective study at University of Gondar Hospital analyzed cutaneous leishmaniasis patients treated from 2022 to 2024. Demographic and epidemiologic data were collected, with parasite detection via microscopic and clinical examination.
Results: Overall, 454 CL cases from 49 districts were diagnosed, predominantly affecting males aged ≤30, with a mean age of 25.31 yr (SD ±18.3). Significant differences were noted in age and sex (P<0.05). Approximately 70% had lesions ≥4 cm. Most CL cases had 2+ parasite loads. Sodium stibogluconate (SSG) remained the primary treatment choice for patients. The spatial distribution of CL cases covered a larger geographical area, although the cases (>20) were concentrated in Central Gondar. The mucosal CL shared a similar geographical pattern with the recurrent CL type. Notably, 48% had chronic presentations and lived with the disease for ≥12 months. In diffuse CL (DCL) a longer delay was seen and its clinical presentation was associated with longitudinal time series. Acute patients exhibited a higher parasitic load than chronic ones (38% vs. 24%), respectively.
Conclusion: CL significantly affected school-aged children. The symmetrical distribution of cases in districts studied could increase the attention of clinicians and enhance management strategies. Extended disease durations necessitated specialized treatments for clinical transitions.
2. Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region / World Health Organization 2014. Regional Office for the Eastern Mediterranean.
3. Volpedo G, Pacheco-Fernandez T, Holcomb EA, Cipriano N, Cox B, Satoskar AR. Mechanisms of immunopathogenesis in cutaneous leishmaniasis and post-kala-azar dermal leishmaniasis (PKDL). Front Cell Infect Microbiol. 2021;11:685296.
4. Elfaki NK, Alzahrani MJ, Abdalla YHA, et al. Perceived social stigma of cutaneous leishmaniasis in Hubuna, Saudi Arabia. J Multidiscip Healthc. 2024;17:867-76.
5. Federal Ministry of Health of Ethiopia: Guideline for the diagnosis, treatment, and prevention of leishmaniasis in Ethiopia. 2nd Edition. 2013.
6. Abadías-Granado I, Diago A, Cerro PA, et al. Cutaneous and Mucocutaneous Leishmaniasis.
7. Actas Dermosifiliogr (Engl Ed). 2021; S0001-7310(21)00108-3.
8. Blaizot R, Pasquier G, Kone AK, Duvignaud A, Demar M. Cutaneous leishmaniasis in sub-Saharan Africa: a systematic review of Leishmania species, vectors and reservoirs. Parasit Vectors. 2024; 17:318.
9. Henten SV, Adriaensen W, Fikre H, et al. Cutaneous leishmaniasis due to Leishmania aethiopica. E Clinical Medicine. 2019; 6:69-81.
10. Gashaw B, Yizengaw E, Yismaw G, et al. Multifaceted impact of cutaneous leishmaniasis: treatment challenges and implications for healthcare systems and society in Boru Meda Hospital, North-Central Ethiopia. Ethiop J Health Dev. 2023; 37(2): doi.org/10.20372/ejhd.v37i2.6120
11. Mbui J, Olobo J, Omollo R, et al. Pharmaco kinetics, safety, and efficacy of Anallometric Miltefosine regimen for the treatment of visceral leishmaniasis in eastern African children: Anopen-label, phase II clinical Trial. Clin Infect Dis. 2019; 68:1530–1538.
12. Bisetegn H, Zeleke AJ, Gadisa E, et al. Clinical, parasitological, and molecular profiles of cutaneous leishmaniasis and its associated factors among clinically suspected patients attending Boru Meda Hospital, North-East Ethiopia. PLoS Negl Trop Dis. 2020;14(8):e0008507.
13. Henten VS, Tesfaye AB, Abdela SG, et al. Miltefosine for the treatment of cutaneous leishmaniasis: a pilot study from Ethiopia. PLoS Negl Trop Dis. 2021;15(5):e0009460.
14. Gashaw B, Yizengaw E, Sebsibe B, et al. Clinical manifestations and traditional practice in patients with cutaneous leishmaniasis: do leishmaniasis induce high blood glucose levels? Ethiop J Health Dev. 2023;37(2).
15. Fikre H, Mohammed R, Atinafu S, et al. Clinical features and treatment response of cutaneous leishmaniasis in North-West Ethiopia. Trop Med Int Health. 2017;22(10):1293–301.
16. Yizengaw E, Gashaw B, Yimer M, et al. Demographic Characteristics and clinical features of patients presenting with different forms of cutaneous leishmaniasis, in Lay Gayint, Northern Ethiopia. PLoS Negl Trop Dis 2024; 18(8):e0012409.
17. Koru K, Beyazgul B, Allahverdi S, Kuzan R. The state of disease-related awareness regarding cutaneous leishmaniasis cases in Sanliurfa, delay level in treatment and reasons for delay. Saudi J Med. 2020 ;5(9):292-9.
18. Merdekios B, Pareyn M, Tadesse D, et al. Detection of cutaneous leishmaniasis foci in South Ethiopia. Am J Trop Med Hyg. 2021;105(1):156–8.
19. Gunasekara SD, Wickramasinghe ND, Agampodi SB, et al. ‘We do not rush to the hospital for ordinary wounds (sulutuvāla)’: A qualitative study on the early clinical manifestations of cutaneous leishmaniasis and associated health behaviors in rural Sri Lanka. PLoS Negl Trop Dis. 2023;17(5):e0010939.
20. Unger A, Neal OS, Machado PRL, et al. Association of treatment of American cutaneous leishmaniasis before ulcer development with a high rate of failure in Northeastern Brazil. Am J Trop Med Hyg. 2009;80(4):574-579.
21. Tegegne B, Alemu G. Progress of mucocutaneous leishmaniasis to drug nonresponsive diffuse cutaneous leishmaniasis in Ethiopia: a case report. Int Med Case Rep J. 2020; 13:551-555.
22. Machado G U, Prates F V, Machado P R L. Disseminated leishmaniasis: clinical, pathogenic, and therapeutic aspects. An Bras Dermatol. 2019;94(1):9-16.
23. Pereira LOR, Moreira RB, Oliveira MP, et al. Is Leishmania (Viannia) braziliensis parasite load associated with disease pathogenesis? Int J Infect Dis. 2017; 57:132-7.
24. Zeinali M, Mohebali M , Shirzadi MR, et al. Integration and evaluation of cutaneous leishmaniasis laboratory diagnosis in the primary health care laboratory network. East Mediterr Health J. 2023; 29(10):810-818.
25. Henten SV, Bialfew F, Hassen S, et al. Treatment of cutaneous leishmaniasis with sodium stibogluconate and allopurinol in a routine setting in Ethiopia: clinical and patient-reported outcomes and operational challenges. Trop Med Infect Dis. 2023; 8(8):414.
Files | ||
Issue | Vol 20 No 2 (2025) | |
Section | Original Article(s) | |
Keywords | ||
Human Ethiopia Cutaneous Leishmaniasis Delay for treatment |
Rights and permissions | |
![]() |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |